Revealing Protective Immunity to Influenza Using Systems Immunology

Announcing PRISM: Revealing Protective Immunity to Influenza Using Systems Immunology

October 16, 2024.

We’re excited to announce PRISM, a groundbreaking clinical study from Atomic Lab. This project explores why the live attenuated influenza vaccine (LAIV) provides exceptional protection in children yet falls short for adults. Indeed, we will look through this PRISM to illuminate what drives long-term immunity against influenza.

We invite healthy adult volunteers (18–49 years old) to join by providing blood and nasal samples. This vital participation will help us understand the immune factors that make LAIV so effective for children. Meanwhile, we know influenza viruses mutate constantly, creating a significant challenge for vaccine development. Current vaccines offer some protection; however, LAIV’s benefits for adults remain limited.

To address this issue, we plan to combine cutting-edge immunology with advanced AI-driven analysis. Consequently, we may pave the way for more potent, longer-lasting flu vaccines. Moreover, this research could bolster global efforts to reduce the impact of influenza, a virus that threatens public health worldwide.

By volunteering, you can help fuel scientific discoveries that may protect millions. We applaud your courage in participating, since your involvement drives breakthroughs in infectious disease prevention. Through PRISM, we aim to clarify how immunity develops, evolves, and, most importantly, endures.

We believe this study will spark new collaborations, promote innovative vaccine strategies, and move us closer to a healthier future. Join us in celebrating this milestone and stay tuned as we shed light on the power of long-term immunity against influenza!

 

You May Also Like…